TransMedics Group (TMDX) Stock Still Looks Reasonable On Earnings Growth

TransMedics Group stock has more than doubled over the past five years, yet the broader valuation checks still lean cheap, which puts fresh attention on whether the recent pullback has gone too far or not far enough.

• Over the past five years, TransMedics Group has returned about 150.4% which keeps the long term story attractive even after a weaker recent stretch.
• Future execution on transplant system adoption can support higher earnings power. However, any slowdown in procedure volumes or pressure on hospital budgets may cap how much investors are willing to pay for that growth.
• The company screens as undervalued on 5 of 6 checks, so the broader valuation work currently leans in favor of the stock looking cheap rather than expensive on Simply Wall St's valuation summary.

The stock's next move may depend on whether that strong long term return and favorable valuation score still offer enough upside to justify the risks in the business model today.

Find out why TransMedics Group's -36.5% return over the last year is lagging behind its peers.

Does TransMedics Group Look Undervalued on Earnings?

The P/E ratio suits TransMedics Group because earnings are a key focus for a business that now generates positive free cash flow. On this metric, TransMedics Group trades at about 15.4x earnings compared with a Medical Equipment industry average of roughly 29.0x and a peer group around 64.8x. That is a large gap to both the sector and similar companies.

The Simply Wall St fair P/E ratio for TransMedics Group is about 24.5x. This fair multiple reflects what investors might typically pay given the company’s mix of growth profile, profitability, size, and risks. The current P/E sits well below that mark, which indicates the market is assigning a lower value to each dollar of TransMedics Group earnings than these benchmarks.

Based on the P/E multiple alone, TransMedics Group stock currently appears undervalued relative to both its tailored fair ratio and industry peers.

See what the numbers say about this price — find out in our valuation breakdown.

The TransMedics Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for TransMedics Group pick up where the valuation puzzle leaves off and explain which paths for growth, margins, and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative treats TransMedics Group's fair value as a thesis about the business that can be tracked over time, rather than a one-off snapshot, and is available on the company’s Community page.

One of the top community narratives on TransMedics Group: 32% undervalued

"Development of a recurring, service-driven revenue model, including logistics, digital ecosystem, and service contracts, enables more predictable and stable cash flows..."

Read one of the top narratives on TransMedics Group

Do you think there's more to the story for TransMedics Group? Head over to our Community to see what others are saying!

The Bottom Line

TransMedics Group screens as undervalued on its earnings multiple, which suggests the current share price does not fully reflect what investors are paying for each dollar of profit. The key question is whether the company can keep building its transplant platform without hitting a wall on procedure volumes or hospital spending. For investors, the crux of the debate is whether the current discount is a genuine opportunity or a sign that the market is already factoring in those execution and budget risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com